Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
NUMIF
)
0.0237
+0.0016 (+7.24%)
Streaming Delayed Price
Updated: 1:05 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about NUMIF
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Psychedelics Co. Numinus Narrows Loss In Q3, Reports QoQ Decrease In Revenue, Gross Profit
July 12, 2024
Psychedelics-focused mental health care company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF), announced on Thursday its third quarter financial results for the three months ended May 31, 2024."In...
Via
Benzinga
Psychedelics-Focused Numinus Plans To Leverage This AI Technology Via New Strategic Acquisition
June 22, 2024
Psychedelics-focused mental healthcare company Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) (FSE: LR23) plans to take over MedBright AI Investments Inc. (CSE: MBA).The proposed transaction comes as...
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
April 15, 2024
Via
Benzinga
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
March 26, 2024
Via
Benzinga
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
March 25, 2024
Via
Benzinga
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
March 16, 2024
Via
Benzinga
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
Via
Benzinga
Why Is MindMed (MNMD) Stock Up 8% Today?
February 12, 2024
MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers.
Via
InvestorPlace
Exposures
Product Safety
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
Numinus Wellness Continues Tight Expense Management With Strategic Reviews Underway
January 18, 2024
Psychedelics mental healthcare company Numinus Wellness (OTCQX: NUMIF) posted its financial results for the three months ended Nov. 30, 2023. Q1 numbers show:
Via
Benzinga
30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond
January 10, 2024
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health...
Via
Benzinga
Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
December 05, 2023
Defense Dept. Funds Ketamine Study For PTSD Treatment
Via
Benzinga
Numinus Reports Q4 & Full Year Fiscal 2023 Results, Including Greatly Reduced Cash Burn Rate
November 30, 2023
Psychedelic therapy clinic provider Numinus Wellness (TSX:NUMI) (OTC: NUMIF) announced
Via
Benzinga
Psychedelics Researchers & Industry Leaders Weigh In On Groundbreaking PTSD Treatment News
September 15, 2023
The long-awaited psychedelic-assisted treatment alternative for Post-Traumatic Stress Disorder (PTSD) is moving closer to federal approval.
Via
Benzinga
NY Consulting Firm Predicts Psychedelic Drugs Market Will Generate Over $12B In Next 12 Years
September 12, 2023
NY-based strategic consulting firm Research Nester launched global market research for psychedelic substances with projections until 2035.
Via
Benzinga
Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031
July 26, 2023
EQNX::TICKER_START (NYSE:CYBN),NEO:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(OTCQX:NUMIF) EQNX::TICKER_END
Via
FinancialNewsMedia
Small Cap Growth Virtual Investor Conference: Presentations Now Available for Online Viewing
July 14, 2023
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
Small Cap Growth Virtual Investor Conference Agenda Announced for July 13th
July 10, 2023
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com
From
Virtual Investor Conferences
Via
GlobeNewswire
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
June 20, 2023
Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice...
Via
Benzinga
Numinus Partners With MAPS To Conduct Phase 1 MDMA Assisted Therapy Investigational Study
June 16, 2023
In a prelude to what is hoped will be regulatory approval of MDMA-assisted therapy in the U.S. and Canada, Numinus Wellness Inc. (OTC: NUMIF) has taken steps to get out in front of the curve.
Via
Benzinga
Numinus' Clinical Arm To Lead Enrollment Site For MindMed's Phase 2b LSD Study
June 05, 2023
Mental healthcare company Numinus Wellness (OTCQX: NUMIF) announced its contract research organization Cedar Clinical Research (CCR) is a top research site for MindMed's (NASDAQ: MNMD) Phase 2b stud
Via
Benzinga
Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
May 31, 2023
Microdosing LSD For Major Depression Treatment Seeks Further Clinical Validation Via New Study Australian psychedelics company MindBio Therapeutics Corp. was granted approval by both the Ethics...
Via
Benzinga
Numinus' Clinical Site Joins Compass' Phase 3 Program On Psilocybin Therapy For TRD
May 30, 2023
Numinus Wellness Inc.’s (OTCMKTS: NUMIF) wholly-owned contract research organization Cedar Clinical Research has commenced a new study on COMPASS Pathways’ (NASDAQ: CMPS) psilocybin therapy for...
Via
Benzinga
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...
Via
Benzinga
Numinus Wellness CEO Payton Nyquvest On Q2 2023 Financial Results And Numinus Network
April 19, 2023
On this new Psychedelic Series Podcast, TDR Founder Shadd Dales spoke with Payton Nyquvest, CEO of Numinus Wellness Inc. (OTC: NUMIF).
Via
Benzinga
Psyched: Clinical-Grade MDMA, LSD For Depression, Partnerships For Delivering Psychedelic Therapies & More
April 17, 2023
Revolutionizing Psychedelics: 2 Industry Leaders Team Up On Clinical-Grade MDMA Capsules
Via
Benzinga
Numinus Q2 2023: 581% Revenue Growth, 820% In Gross Profit And Strong Cash Position
April 14, 2023
Psychedelics mental healthcare company Numinus Wellness Inc. (OTCQX: NUMIF) announced its financial results for the three and six months ended Feb. 28, 2023. Q2 numbers show: Total cash of $14.7...
Via
Benzinga
EXCLUSIVE: Infrastructure Built For Healing: 'Consolidation And Legitimacy Are Crucial For Psychedelic Industry Growth'
April 13, 2023
“Investing in real estate can help expand experiential medicines like ketamine and MDMA for treating PTSD and build infrastructure for upcoming FDA-approved therapies,” said Daniel Carcillo, founder...
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 13, 2023
April 13, 2023
Via
Benzinga
Psychedelic Stock Gainers And Losers From April 12, 2023
April 12, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.